Jasper Therapeutics, Inc. (JSPR)·Q3 2025 Earnings Summary

Executive Summary

• Q3 showed tighter cost control and a smaller loss: net loss of $18.7M (EPS $(1.13)), with R&D $14.4M and G&A $4.8M; cash and equivalents were $50.9M as of 9/30/25 .
• Company completed a $30M equity/warrant financing in September, with management stating the raise “extends Jasper’s cash runway through the first half of 2026,” while the 10‑Q simultaneously flagged substantial doubt about going concern without further financing, highlighting financing risk despite the raise .
• Anomalous efficacy results in two BEACON CSU cohorts were preliminarily determined not related to drug substance/product; the investigation now centers on clinical site activity, with final conclusions targeted for Q4 2025—a key near‑term catalyst .
• Development timelines slid: Phase 2b in CSU now expected mid‑2026 (from prior Q4 2025), with additional BEACON/OLE data anticipated in early Q1 2026 and initial ETESIAN (asthma) data planned for Q4 2025, making Q4–Q1 readouts the stock’s next drivers .

What Went Well and What Went Wrong

• What Went Well

  • Financing and runway: Completed $30M underwritten offering; management indicated runway through H1 2026, alleviating near‑term liquidity pressure and enabling continued program execution .
  • Manufacturing risk de‑risked: Investigation to date indicates BEACON anomalous efficacy is not related to DS/DP manufacturing or distribution, refocusing root‑cause analysis to clinical sites; CEO: “We…believe that briquilimab has the potential to serve as a highly differentiated therapeutic…” .
  • Operating discipline: Q3 R&D/G&A fell sequentially from Q2 (R&D $14.4M vs. $21.2M; G&A $4.8M vs. $5.9M) following a 50% workforce reduction in July, demonstrating early impact of restructuring .

• What Went Wrong

  • Program execution risk persists: Two BEACON cohorts (240mg Q8W and 240→180mg Q8W) showed atypical absence of UAS7 reduction (11/13 patients) and remain under investigation, delaying dose selection and pushing Phase 2b to mid‑2026 .
  • Going concern and legal overhang: 10‑Q disclosed substantial doubt about going concern over the next 12 months absent further financing; new shareholder class action and a derivative suit were filed, adding cost/distraction risk .
  • Asthma program pause: ETESIAN enrollment was halted in July given supply overlap with the investigated BEACON lot; initial data now planned for Q4 2025, later than earlier targets .

Financial Results

Notes:

• Q3 tables also reported warrant liability ($22.6M) and offering costs in other expense ($2.0M), reflecting September financing and related accounting .

Guidance Changes

Earnings Call Themes & Trends

Note: No Q3 2025 earnings call transcript was posted on the company’s IR site/filings; themes reflect press releases and 10‑Q .

Management Commentary

• CEO Ronald Martell: “We remain focused on advancing our programs in chronic urticaria and continue to believe that briquilimab has the potential to serve as a highly differentiated therapeutic… Our investigation…is nearing completion…results…do not appear to be related to any issues with drug substance or drug product” .
• Interim CMO (Q2) Daniel Adelman, M.D.: “We are pursuing a number of avenues of investigation…lack of any observed dose‑limiting safety signals…enables us to…redose…as well as [to] enroll an additional 10–12 new patients across those cohorts” .
• On capital: “Successfully completed a $30 million underwritten offering…extends Jasper’s cash runway through the first half of 2026” .

Q&A Highlights

• An earnings call transcript was not available for Q3 2025 on the company’s IR site/filings; guidance and clarifications relied on the 8‑K press release and the 10‑Q .

Estimates Context

• Wall Street consensus (S&P Global) for Q3 2025 revenue/EPS was unavailable for JSPR this quarter; as a pre‑revenue clinical-stage biotech, estimate coverage may be limited. Values retrieved from S&P Global.

KPIs and Program Context

Clear Implications and Drivers

• Near‑term catalysts: (1) Q4 2025 investigation conclusions, (2) Q4 2025 ETESIAN data, (3) early Q1 2026 BEACON/OLE data—each can shift the Phase 2b dose strategy and sentiment on efficacy consistency .
• Financing path: Despite the $30M raise and stated runway to H1’26, management still discloses going concern risk in the 10‑Q, implying a need to use the remaining ATM capacity ($93.5M) and/or pursue strategic capital before mid‑2026 .
• Legal risk: New class and derivative actions create incremental spend and attention drag; outcomes uncertain but pose headline risk .

Key Takeaways for Investors

• The manufacturing de‑risking (DS/DP not implicated) is positive; focus shifts to site/patient‑handling factors that may be addressable operationally—watch Q4 conclusions for corrective actions and generalizability across sites .
• Timeline reset is now clear: Phase 2b CSU mid‑2026; near‑term data cadence (Q4/Q1) is critical to restore confidence in dose selection and efficacy consistency .
• Liquidity improved with $30M raise and sizable shelf/ATM capacity remaining, but the 10‑Q going‑concern language underscores continued financing risk; dilution and warrant overhang are relevant factors .
• Cost base trending down post‑restructuring (Q3 OpEx step‑down vs. Q2) supports runway preservation while management concentrates spend on urticaria programs .
• Legal overhang adds uncertainty and potential expense; monitor case progress and any settlements/insurance offsets .
• Stock set‑up into Q4/Q1: High event sensitivity; positive investigation readout plus corroborating BEACON/OLE data could re‑rate the program; further execution issues or equivocal data could pressure shares, especially amid financing needs .

---

Sources: Q3 2025 8‑K press release and exhibits ; Q3 2025 10‑Q (financials, MD&A, risk factors) ; Q2 2025 8‑K press release ; Q1 2025 8‑K press release ; July 9, 2025 reorganization PR ; Nov 4, 2025 conference participation PR .